MG
TARS icon

Michael Gelband’s Tarsus Pharmaceuticals TARS Stock Holding History

Michael Gelband’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Sell
20,250
-10,070
-33% -$643K 0.01% 996
2026
Q1 		$2.13M Sell
30,320
-21,167
-41% -$1.48M 0.02% 762
2025
Q4 		$4.22M Buy
+51,487
New +$3.84M 0.03% 540
2024
Q4 		– Sell
-883,043
Closed -$29M – 2046
2024
Q3 		$29M Buy
883,043
+212,584
+32% +$5.98M 0.18% 96
2024
Q2 		$18.2M Buy
670,459
+454,501
+210% +$15.3M 0.12% 145
2024
Q1 		$7.85M Sell
215,958
-16,942
-7% -$498K 0.06% 251
2023
Q4 		$4.72M Sell
232,900
-165,741
-42% -$2.77M 0.03% 357
2023
Q3 		$7.08M Buy
398,641
+203,820
+105% +$3.61M 0.07% 296
2023
Q2 		$3.52M Buy
+194,821
New +$3.1M 0.03% 580

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's TARS Position: Q2 2026 in Review

Michael Gelband reduced its Tarsus Pharmaceuticals (TARS) stake by 33% in Q2 2026, selling an estimated $643K and leaving 20,250 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #996.

Michael Gelband first reported a position in TARS in Q2 2023 and has held it in 9 quarters since. The position peaked at $29M in Q3 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Michael Gelband held 20,250 shares of Tarsus Pharmaceuticals worth $1.27M as of Q2 2026.
  • Michael Gelband sold 10,070 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $643K.
  • Tarsus Pharmaceuticals made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #996 holding.
  • Michael Gelband first reported a position in Tarsus Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
  • Michael Gelband's Tarsus Pharmaceuticals position peaked at $29M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.